These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
616 related articles for article (PubMed ID: 24244610)
1. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610 [TBL] [Abstract][Full Text] [Related]
2. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs. Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V Front Immunol; 2021; 12():716559. PubMed ID: 34335631 [TBL] [Abstract][Full Text] [Related]
3. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005 [TBL] [Abstract][Full Text] [Related]
4. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208 [TBL] [Abstract][Full Text] [Related]
5. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Zhang S; Ke X; Zeng S; Wu M; Lou J; Wu L; Huang P; Huang L; Wang F; Pan S Cell Mol Immunol; 2015 Sep; 12(5):580-91. PubMed ID: 26166762 [TBL] [Abstract][Full Text] [Related]
6. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Sato E; Olson SH; Ahn J; Bundy B; Nishikawa H; Qian F; Jungbluth AA; Frosina D; Gnjatic S; Ambrosone C; Kepner J; Odunsi T; Ritter G; Lele S; Chen YT; Ohtani H; Old LJ; Odunsi K Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18538-43. PubMed ID: 16344461 [TBL] [Abstract][Full Text] [Related]
7. Providence of the CD25 Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737 [TBL] [Abstract][Full Text] [Related]
8. Increased frequency and FOXP3 expression of human CD8 Zahran AM; Nafady-Hego H; Mansor SG; Abbas WA; Abdel-Malek MO; Mekky MA; Hetta HF Hum Immunol; 2019 Jul; 80(7):510-516. PubMed ID: 30904437 [TBL] [Abstract][Full Text] [Related]
9. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917 [TBL] [Abstract][Full Text] [Related]
10. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients. Mohammadnia-Afrouzi M; Zavaran Hosseini A; Khalili A; Abediankenari S; Hosseini V; Maleki I Autoimmunity; 2015; 48(8):556-61. PubMed ID: 26333292 [TBL] [Abstract][Full Text] [Related]
11. Aberrant peripheral blood CD4 Dehghani M; Kalani M; Golmoghaddam H; Ramzi M; Arandi N Cancer Immunol Immunother; 2020 Sep; 69(9):1917-1928. PubMed ID: 32385519 [TBL] [Abstract][Full Text] [Related]
12. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Yip WK; Abdullah MA; Yusoff SM; Seow HF Clin Exp Immunol; 2009 Mar; 155(3):412-22. PubMed ID: 19220831 [TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment. Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534 [TBL] [Abstract][Full Text] [Related]
14. Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio. Azzimonti B; Zavattaro E; Provasi M; Vidali M; Conca A; Catalano E; Rimondini L; Colombo E; Valente G Br J Dermatol; 2015 Jan; 172(1):64-73. PubMed ID: 24910265 [TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4 Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829 [TBL] [Abstract][Full Text] [Related]
16. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Wolf D; Wolf AM; Rumpold H; Fiegl H; Zeimet AG; Muller-Holzner E; Deibl M; Gastl G; Gunsilius E; Marth C Clin Cancer Res; 2005 Dec; 11(23):8326-31. PubMed ID: 16322292 [TBL] [Abstract][Full Text] [Related]
17. CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer. deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168 [TBL] [Abstract][Full Text] [Related]
18. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Shah W; Yan X; Jing L; Zhou Y; Chen H; Wang Y Cell Mol Immunol; 2011 Jan; 8(1):59-66. PubMed ID: 21200385 [TBL] [Abstract][Full Text] [Related]
19. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer. De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619 [TBL] [Abstract][Full Text] [Related]
20. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]